Enjoy complimentary customisation on priority with our Enterprise License!
According to the solid tumors drugs industry analysis, this market is projected to witness staggering growth and will post an impressive CAGR of more than 8% over the forecast period. The growing incidence of solid tumors worldwide has resulted in pharmaceutical companies investing heavily in R&D to provide more efficacious and better-tolerated medications. The clinical pipeline for solid tumors is vast, featuring drugs in different stages of development. Moreover, many companies are set to launch 2 to 3 new drugs, which are now in the pipeline, during the forecast period. Around 30% of all biologics awaiting the US FDA’s approval are monoclonal antibodies for the treatment of solid tumors. Some of these drugs include Elotuzumab, Avelumab, and biosimilars of Avastin, MabThera, and Herceptin. Besides these, some molecules are in Phase I/II, pre-clinical, and discovery stages, which will form a robust pipeline for solid tumors in the coming years.
The emergence of biosimilars is one of the emerging solid tumors drugs market trends spurring the growth prospects for this market during the forecast period. Biosimilars, unlike generic drugs, are almost similar to the originator biologic compounds. When developed by different manufacturers, these drugs can differ from the original product, as well as from each other. Also, they cost less than biologics and are therefore more accessible to patients. Some of the major biologics available for the treatment of solid tumors include MabThera, Avastin, Herceptin, Erbitux, and Vectibix. However, patent expiries of the major biologics will result in the emergence of the biosimilars of these drugs. The sales of these biologics may decline during the forecast period due to growth in the sales of their biosimilar versions.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Cost analysis
PART 06: Pipeline portfolio
PART 07: Market landscape
PART 08: Market segmentation by molecule type
PART 09: Market segmentation by type of therapy
PART 10: Market segmentation by disease
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
PART 18: Appendix
PART 19: Explore Technavio
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.